So, it has been proposed that ERG-driven drug resistance overrides PI3K/AKT signaling by alternative pathways which need to be further investigated for effective drug design and adapted therapies for ERG-overexpressing high-risk leukemias [6,7]. The gene discussed is ERG; the disease is leukemia.